Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients [Letter]

Platzbecker, U., Al-Ali, H. K., Gattermann, N., Haase, D., Janzen, V., Krauter, J., Goetze, K., Schlenk, R., Nolte, F., Letsch, A., Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Kuendgen, A., Luebbert, M., Germing, U., Wermke, M., Reinhard, H., Weiss, C., Lieder, K., Ehninger, G., Leismann, O. and Giagounidis, A. 2014. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients [Letter]. Leukemia 28 (3) , pp. 696-698. 10.1038/leu.2013.325

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Springer Nature
ISSN:	0887-6924
Last Modified:	02 Nov 2022 09:55
URI:	https://orca.cardiff.ac.uk/id/eprint/96799

Citation Data

Cited 20 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item